Temasek, HongShan-backed D3 Bio raises $108m in Series B round

Temasek, HongShan-backed D3 Bio raises $108m in Series B round

Innovative Drugs

10 December, 2025

Edited by: Joymitra Rai

biotech D3 Bio D3S-001 HSG IDG Capital oncology therapeutics SongQing Capital Temasek

Printed by Unregistered user on Wed, 10 Dec 2025 10:21:35 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Italy's Angelini Ventures opens SG office to grow Asia biotech portfolio

China's Sunho Biotech acquires SG-based waste management firm

Read more from Greater China

Earnings and Results

Chinese sovereign wealth fund CIC’s profit soars 30.4% on investment gains

China sovereign fund SAFE IC in talks to sell $1b private fund stakes